Skip to main content
SpringerLink
Log in

CpG 7909

PF 3512676, PF-3512676

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Pfizer Inc, Coley Pharmaceutical Group Inc. Pfizer, Coley Pharmaceutical Group Enter Into Exclusive Global License For The Development and Commercialization of ProMune(TM) for Cancers. Media Release: 24 Mar 2005. Available from URL: http://www.pfizer.com

    Google Scholar 

  2. Novartis. Novartis Creates New Vaccines Division Following Close of Chiron Deal. Media Release: 20 Apr 2006. Available from URL: http://www.pharmtech.com

    Google Scholar 

  3. Coley Pharmaceutical Group Inc. Coley Pharmaceutical Group Licenses VaxImmune(TM) Vaccine Adjuvant to Chiron Corporation for Inclusion in New Infectious Disease Vaccines. Media Release: 23 Dec 2003. Available from URL: http://www.coleypharma.com

    Google Scholar 

  4. Coley Pharmaceutical Group, GlaxoSmithKline. Coley Pharmaceutical Group and GlaxoSmithKline enter into license agreement for development of cancer vaccines. Media Release: 19 Nov 2002. Available from URL: http://www.coleypharma.com

    Google Scholar 

  5. Coley Pharmaceutical Group. Coley Pharmaceutical Group Announces $16.9 Million Research Contract From NIH for Development of New Vaccine Adjuvants for Biodefense. Media Release: 21 Sep 2004. Available from URL: http://www.coleypharma.com

    Google Scholar 

  6. Coley Pharmaceutical Group Inc. Coley Pharmaceutical Group Reports First Quarter Financial Results. Media Release: 11 May 2006. Available from URL: http://www.coleypharma.com

    Google Scholar 

  7. Coley Pharmaceutical Group Inc. Coley Pharmaceutical Group Announces Commencement of Phase III Clinical Trials of PF-3512676 for Advanced NSCLC. Media Release: 28 Nov 2005. Available from URL: http://www.coleypharma.com

    Google Scholar 

  8. Wooldridge J, Link BK, Weisdorf DJ et al. Phase I study of oligodeoxynucleotide CpG 7909 in patients with previously treated non-Hodgkin’s lymphoma. 39th Annual Meeting of the American Society of Clinical Oncology: 210, 31 May 2003

  9. Krieg A, Efler S, Price J. et al. Biomarker profile and clinical safety of S.C. or I.V. doses of Promune (TM) (CpG 7909 injection) a novel TLR-9 agonist oligodeoxyucleotide. Journal of Immunotherapy 26: 34, No. 6, Nov-Dec 2003

    Google Scholar 

  10. Kim YH, Girardi M, Duvic M et al. Cutaneous T cell lymphoma response to a TLR9 agonist CPG: a phase I/II study. Journal of Investigative Dermatology 122: A58, No. 3, Mar 2004

    Google Scholar 

  11. Weiner GJ, Link BK, Leonard J et al. Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL): a phase I, open label doseescalation study of safety and tolerability. 40th Annual Meeting of the American Society of Clinical Oncology: 579 (plus poster) abstr. 6594, 6 Jun 2004

    Google Scholar 

  12. Leichman G, Gravenor D, Woytowitz D et al. CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study. Journal of Clinical Oncology 23 (Suppl.): 630 (plus poster) abstr. 7039, No. 16, Part I, 1 Jun 2005

    Google Scholar 

  13. Rynkiewicz D, Rathkopf M, Ransom J et al. Marked enhance ment of antibody response to anthrax vaccine adsorbed with CPG 7909 in healthy volunteers. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: Final Program: 214 (plus poster) abstr. LB-25, Dec 2005

    Google Scholar 

  14. Pashenkov M, Goess G, Wagner C et al. Cancer regression induced by TLR9-targeted immunostimulatory CpG treatment in patients with metastatic melanoma: results of a clinical phase II trial. Journal of Investigative Dermatology 122: A58, No. 3, Mar 2004

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

CpG 7909. Drugs R D 7, 312–316 (2006). https://doi.org/10.2165/00126839-200607050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200607050-00004

Keywords

Search

Navigation